- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | Canaccord reiterates TriSalus stock Buy rating after KOL event | 1 | Investing.com | ||
| 18.05. | TriSalus Life Sciences: Aktie steigt trotz Umsatzrückgang im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 13.05. | TriSalus outlines $54M-$57M 2026 revenue forecast while TriNav Advance clearance runs ~5 months past goal | 1 | Seeking Alpha | ||
| 12.05. | TriSalus Life Sciences Q1 2026 Earnings Call: Complete Transcript | 2 | Benzinga.com | ||
| 12.05. | TriSalus Life Sciences GAAP EPS of $0.03 beats by $0.19, revenue of $8.9M misses by $1.54M | 2 | Seeking Alpha | ||
| 12.05. | TriSalus senkt Umsatzprognose für 2026 auf 54-57 Mio. US-Dollar | 3 | Investing.com Deutsch | ||
| 12.05. | TriSalus Life Sciences, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 04.05. | TriSalus startet PREDICTT-Studie zur Behandlung von Lebertumoren | 1 | Investing.com Deutsch | ||
| TRISALUS LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 04.05. | TriSalus initiates PREDICTT trial for liver tumor treatment | 1 | Investing.com | ||
| 09.04. | TriSalus to present drug delivery data at radiology meeting | 1 | Investing.com | ||
| 07.04. | TriSalus ernennt Richard Marshall zum Chief Medical Officer | 2 | Investing.com Deutsch | ||
| 07.04. | TriSalus names Richard Marshall as chief medical officer | 2 | Investing.com | ||
| 07.04. | TriSalus Life Sciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | TriSalus publishes preclinical data on drug delivery technology | 1 | Investing.com | ||
| 06.03. | Jones Trading bestätigt Kaufempfehlung für TriSalus Life Sciences nach Geschäftszahlen | 1 | Investing.com Deutsch | ||
| 06.03. | Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings | 2 | Investing.com | ||
| 06.03. | TriSalus Life Sciences reaffirms $60M-$62M revenue guidance for 2026 while expanding PEDD portfolio | 1 | Seeking Alpha | ||
| 05.03. | TriSalus Life Sciences: Umsatz steigt im vierten Quartal um 60 % | 3 | Investing.com Deutsch | ||
| 05.03. | TriSalus Life Sciences, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Earnings Summary: TriSalus Life Sciences Q4 | 1 | Benzinga.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TILRAY BRANDS | 3,805 | -0,78 % | Tilray-Aktie: Startet jetzt die 700%-Chance? | Die Tilray-Aktie hat in den vergangenen Tagen eine bemerkenswerte Kehrtwende vollzogen. Nach enttäuschenden Quartalszahlen am 28. Juli geriet der Cannabis-Titel zunächst unter Druck, ehe bereits einen... ► Artikel lesen | |
| VIATRIS | 15,260 | -0,05 % | Weekly Buzz: Cipla, Viatris Win FDA Nod; Boston Scientific Cuts Jobs; argenx Snaps Up Forte Biosciences; Johnson & Johnson, GSK Strike Deals | NEW BRUNSWICK (dpa-AFX) - The healthcare sector delivered another eventful week, marked by major regulatory approvals, strategic partnerships, acquisitions, restructuring initiatives and significant... ► Artikel lesen | |
| SYNBIOTIC | 1,050 | -4,37 % | EQS-Adhoc: SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung von Insolvenzverfahren zu stellen | EQS-Ad-hoc: SYNBIOTIC SE / Schlagwort(e): Strategische Unternehmensentscheidung/Insolvenz
SYNBIOTIC SE: SOLIDMIND Group GmbH und Lean Labs Pharma GmbH beabsichtigen, Anträge auf Eröffnung... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 9,910 | +1,79 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. | ||
| SELLAS LIFE SCIENCES | 10,200 | -0,97 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,814 | -3,69 % | XORTX Therapeutics Inc.: XORTX Announces Director Resignation | CALGARY, Alberta, July 31, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| SOLIGENIX | 0,383 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| TALPHERA | 1,160 | +2,65 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,683 | -1,93 % | Savara Inc.: Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 | -- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI's Proprietary eFlow Nebulizer System... ► Artikel lesen | |
| SCYNEXIS | 5,220 | 0,00 % | Brookline bestätigt Kursziel für Scynexis von 44,64 USD und sieht massives Aufwärtspotenzial | ||
| THERIVA BIOLOGICS | 0,225 | 0,00 % | Theriva Biologics, Inc. - 8-K, Current Report | ||
| WAVE LIFE SCIENCES | 4,960 | -3,69 % | Wave Life Sciences Ltd.: Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update | Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 1,870 | +2,75 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers | The IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination... ► Artikel lesen | |
| THERAPEUTICSMD | 1,700 | -1,73 % | TherapeuticsMD, Inc. - 8-K, Current Report | ||
| YARROW BIOSCIENCE | 37,825 | +0,33 % | Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves Disease and Thyroid Eye Disease | Yarrow is advancing YB-101-a potential first-in-class anti-TSHR antibody, designed to directly disrupt the central mechanism driving both Graves' disease ("GD") and thyroid eye disease ("TED")
Dosing... ► Artikel lesen |
TRISALUS LIFE SCIENCES INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 4,610 Euro und damit -0,22 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRISALUS LIFE SCIENCES INC finden Sie auf Wallstreet Online.